JP2004530641A5 - - Google Patents

Download PDF

Info

Publication number
JP2004530641A5
JP2004530641A5 JP2002552936A JP2002552936A JP2004530641A5 JP 2004530641 A5 JP2004530641 A5 JP 2004530641A5 JP 2002552936 A JP2002552936 A JP 2002552936A JP 2002552936 A JP2002552936 A JP 2002552936A JP 2004530641 A5 JP2004530641 A5 JP 2004530641A5
Authority
JP
Japan
Prior art keywords
group
carbon atoms
ylmethyl
linear
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002552936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004530641A (ja
JP4445704B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/015169 external-priority patent/WO2002051841A1/en
Publication of JP2004530641A publication Critical patent/JP2004530641A/ja
Publication of JP2004530641A5 publication Critical patent/JP2004530641A5/ja
Application granted granted Critical
Publication of JP4445704B2 publication Critical patent/JP4445704B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002552936A 2000-12-22 2001-12-20 キヌクリジンカルバメート誘導体およびm3アンダゴニストとしてのそれらの使用 Expired - Fee Related JP4445704B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200003084 2000-12-22
PCT/EP2001/015169 WO2002051841A1 (en) 2000-12-22 2001-12-20 Quinuclidine carbamate derivatives and their use as m3 antagonists

Publications (3)

Publication Number Publication Date
JP2004530641A JP2004530641A (ja) 2004-10-07
JP2004530641A5 true JP2004530641A5 (OSRAM) 2006-01-05
JP4445704B2 JP4445704B2 (ja) 2010-04-07

Family

ID=8496114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002552936A Expired - Fee Related JP4445704B2 (ja) 2000-12-22 2001-12-20 キヌクリジンカルバメート誘導体およびm3アンダゴニストとしてのそれらの使用

Country Status (32)

Country Link
US (3) US7208501B2 (OSRAM)
EP (1) EP1345937B1 (OSRAM)
JP (1) JP4445704B2 (OSRAM)
KR (1) KR100869722B1 (OSRAM)
CN (1) CN1298717C (OSRAM)
AR (1) AR035410A1 (OSRAM)
AT (1) ATE305468T1 (OSRAM)
AU (1) AU2002228015B2 (OSRAM)
BG (1) BG107930A (OSRAM)
BR (1) BR0116450A (OSRAM)
CA (1) CA2441896A1 (OSRAM)
CZ (1) CZ301323B6 (OSRAM)
DE (1) DE60113719T2 (OSRAM)
DK (1) DK1345937T3 (OSRAM)
EC (1) ECSP034660A (OSRAM)
EE (1) EE200300295A (OSRAM)
ES (1) ES2248409T3 (OSRAM)
HU (1) HUP0303529A3 (OSRAM)
IL (1) IL156499A0 (OSRAM)
MX (1) MXPA03005583A (OSRAM)
MY (1) MY136674A (OSRAM)
NO (1) NO328707B1 (OSRAM)
NZ (1) NZ526580A (OSRAM)
PE (1) PE20020719A1 (OSRAM)
PL (1) PL362989A1 (OSRAM)
RU (1) RU2296762C2 (OSRAM)
SI (1) SI1345937T1 (OSRAM)
SK (1) SK8002003A3 (OSRAM)
UA (1) UA76131C2 (OSRAM)
UY (1) UY27092A1 (OSRAM)
WO (1) WO2002051841A1 (OSRAM)
ZA (1) ZA200304769B (OSRAM)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IL153707A0 (en) 2000-06-27 2003-07-06 S A L V A T Lab Sa Carbamates derived from arylalkylamines
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
CA2433128C (en) 2000-12-28 2010-05-25 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
CA2470567A1 (en) 2001-12-14 2003-06-26 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
EA006505B1 (ru) * 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
CN1668585A (zh) * 2002-07-08 2005-09-14 兰贝克赛实验室有限公司 用作蝇蕈碱受体拮抗剂的3,6-二取代氮杂双环[3.1.0]己烷衍生物
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7358244B2 (en) 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
EP1644356A1 (en) 2003-07-11 2006-04-12 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
CN100569760C (zh) 2003-11-21 2009-12-16 施万制药 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JP2007528416A (ja) 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
US7501442B2 (en) 2004-03-11 2009-03-10 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087739A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7262205B2 (en) 2004-03-11 2007-08-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723115A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528412A (ja) 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
WO2006099032A1 (en) 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200714587A (en) 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008537931A (ja) 2005-03-10 2008-10-02 セラヴァンス, インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
US7659403B2 (en) 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7642355B2 (en) 2005-03-10 2010-01-05 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7728144B2 (en) 2005-06-13 2010-06-01 Theravance, Inc Biphenyl compounds useful as muscarinic receptor antagonists
ATE482959T1 (de) 2005-08-22 2010-10-15 Targacept Inc Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Il13に対するヒト抗体および治療的使用
EP1968980A1 (en) * 2005-12-30 2008-09-17 Ranbaxy Laboratories, Ltd. Muscarinic receptor antagonists
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP1882691A1 (en) 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Quinuclidine derivatives as M3 antagonists
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Pi3k 지질 키나제 억제제로서의 피라졸로피리미딘
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
CA2673803A1 (en) 2007-01-10 2008-07-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
JP5293192B2 (ja) * 2007-02-09 2013-09-18 アステラス製薬株式会社 アザ架橋環化合物
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CN101883771A (zh) 2007-10-01 2010-11-10 科门蒂斯公司 作为α7-烟碱乙酰胆碱受体配体用于治疗阿尔茨海默氏病的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
EP2065385A1 (en) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
KR101578235B1 (ko) 2007-12-10 2015-12-16 노파르티스 아게 유기 화합물
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
EP2080507A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulations comprising an anticholinergic drug
EP2633868A1 (en) 2008-02-13 2013-09-04 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
NZ587561A (en) 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
AU2009256645A1 (en) 2008-06-10 2009-12-17 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
WO2010045633A2 (en) * 2008-10-17 2010-04-22 National Jewish Health Measurement and analysis of leukotrienes
EP2206712A1 (en) * 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
CN102573846B (zh) 2009-08-17 2015-10-07 因特利凯公司 杂环化合物及其用途
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
KR20130087405A (ko) * 2010-06-22 2013-08-06 키에시 파르마슈티시 엣스. 피. 에이. 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물
KR20130087406A (ko) 2010-06-22 2013-08-06 키에시 파르마슈티시 엣스. 피. 에이. 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물
KR20130111968A (ko) * 2010-06-22 2013-10-11 키에시 파르마슈티시 엣스. 피. 에이. 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물
NZ604983A (en) 2010-06-22 2014-07-25 Chiesi Farma Spa Dry powder formulation comprising an antimuscarinic drug
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2643295B1 (en) * 2010-11-26 2016-04-13 Chiesi Farmaceutici S.p.A. Glycine derivatives and their use as muscarinic receptor antagonists
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US20120220557A1 (en) 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Trk阻害剤としてのピラゾロ[1,5−a]ピリジン
LT3673906T (lt) * 2011-03-18 2025-08-11 Genzyme Corporation Gliukozilceramido sintazės inhibitoriai
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
BR112013025682A2 (pt) * 2011-04-29 2017-01-03 Chiesi Farm Spa Compostos, composição farmacêutica, uso de um composto, combinação e dispositivo
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
EP2755967B1 (en) 2011-09-16 2015-10-21 Novartis AG Heterocyclic compounds for the treatment of cystic fibrosis
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
BR112014013179A2 (pt) 2011-12-30 2017-06-13 Chiesi Farm Spa compostos, combinação de um composto, composição farmacêutica e usos de um composto
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
EA201692140A1 (ru) 2014-04-24 2017-04-28 Новартис Аг Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы
JP6404944B2 (ja) 2014-04-24 2018-10-17 ノバルティス アーゲー ホスファチジルイノシトール3−キナーゼ阻害薬としてのピラジン誘導体
JP2017524736A (ja) 2014-07-11 2017-08-31 アルファーマゲン,エルエルシー アルファ7−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
EP3980121A1 (en) 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CN114341132A (zh) 2019-08-28 2022-04-12 诺华股份有限公司 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
MX2023001014A (es) 2020-07-24 2023-03-01 Genzyme Corp Composiciones farmaceuticas que comprenden venglustat.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2762796A (en) 1956-09-11 Iminodibenzyl derivative
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
GB1246606A (en) 1969-04-28 1971-09-15 Starogardzkie Zakl Farma Dibenzo-azepine derivatives
IL72788A (en) 1984-08-28 1989-07-31 Israel State Bis quaternary oxy-bis methylene(or trimethylene)bis-n-quinuclidines,pyridines and piperidines,their preparation and antidotes against organophosphorus and carbamate poisoning containing them
GB2225574B (en) * 1987-12-24 1991-04-24 Wyeth John & Brother Ltd Heterocyclic compounds
US5066680A (en) * 1989-02-14 1991-11-19 Fujisawa Pharmaceutical Co., Ltd. Novel substituted-acetamide compound and a process for the preparation thereof
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
GB9119705D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
GB9201751D0 (en) 1992-01-28 1992-03-11 Smithkline Beecham Plc Compounds
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
AU685225B2 (en) * 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
CN1140447A (zh) * 1994-02-10 1997-01-15 山之内制药株式会社 新的氨基甲酸酯衍生物及其药物组合物
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
US6130232A (en) 1995-10-13 2000-10-10 Banyu Pharmaceutical Coaltd Substituted piperidine derivatives as muscarinic M3 receptor antagonists
AUPN862996A0 (en) 1996-03-13 1996-04-04 Fujisawa Pharmaceutical Co., Ltd. A novel substituted-acetamide compound
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IL153707A0 (en) * 2000-06-27 2003-07-06 S A L V A T Lab Sa Carbamates derived from arylalkylamines
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
CA2433128C (en) 2000-12-28 2010-05-25 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
EA006505B1 (ru) * 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US6946828B1 (en) * 2003-05-20 2005-09-20 Ami Semiconductor, Inc. Bi-directional current measurement circuit that uses a transconductance amplifier to generate a copy current
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
AU2005312076A1 (en) * 2004-12-03 2006-06-08 Merck & Co., Inc. 8-phenyl-5,6,7,8-hydroquinoline tachykinin receptor antagonists
EP1882691A1 (en) 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Quinuclidine derivatives as M3 antagonists
EP2065385A1 (en) 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist

Similar Documents

Publication Publication Date Title
JP2004530641A5 (OSRAM)
JP2003501474A5 (OSRAM)
JP2001525411A5 (OSRAM)
MXPA03005583A (es) Derivados de carbamato de quinuclidina y su uso como antagonistas m3.
JP2006521359A5 (OSRAM)
JP2004516314A5 (OSRAM)
JP2003531118A5 (OSRAM)
JP2002519425A5 (OSRAM)
JP2005538057A5 (OSRAM)
WO2001087845A3 (en) N-containing heterocyclic compounds and their use as 5-ht antagonists
JP2001526218A5 (OSRAM)
JP2005511697A5 (OSRAM)
JP2002543114A5 (OSRAM)
JPH1180090A5 (OSRAM)
RU96107392A (ru) Фотосенсибилизаторы
JP2003261873A5 (OSRAM)
JP2004510813A5 (OSRAM)
JP2002506864A5 (OSRAM)
JP2005511594A5 (OSRAM)
JP2007517037A5 (OSRAM)
JP2002520286A5 (OSRAM)
JP2002523496A5 (OSRAM)
JP2006518765A5 (OSRAM)
JP2003513075A5 (OSRAM)
JP2005527479A5 (OSRAM)